Sign Up
Stories
GI Innovations Unveiled at DDW 2024
Share
Advancements in Cancer Treatment and Mar...
Biosimilar Partnership in U.S.
Innovative Therapeutics Insights 2024
89bio to Present pegozafermin for NASH a...
ANJESO Drug Insight and Market Forecast
CDI Prevention Drug Advances
Overview
API
Ironwood Pharmaceuticals will present new data on apraglutide in short bowel syndrome with intestinal failure (SBS-IF) at DDW 2024, aiming to submit an NDA to the FDA for apraglutide. They will also highlight data on linaclotide for IBS-C and FC, strengthening their presence in the GI treatment market.
Ask a question
How might the new data on apraglutide impact the treatment landscape for SBS-IF?
In what ways could Ironwood's advancements influence the development of future GI treatments?
What competitive advantages could Ironwood gain by showcasing linaclotide data at DDW 2024?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Feb 2024
Mar 2024
Apr 2024
Coverage